Development of antirituximab antibodies in children with nephrotic syndrome

被引:33
作者
Ahn, Yo Han [1 ]
Kang, Hee Gyung [1 ,2 ]
Lee, Jiwon M. [1 ]
Choi, Hyun Jin [1 ]
Ha, Il-Soo [1 ,3 ]
Cheong, Hae Il [1 ,2 ,3 ]
机构
[1] Seoul Natl Univ, Childrens Hosp, Dept Pediat, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Res Coordinat Ctr Rare Dis, Seoul 110744, South Korea
[3] Seoul Natl Univ, Coll Med, Med Res Ctr, Kidney Res Inst, Seoul, South Korea
关键词
Nephrotic syndrome; Rituximab; Human antichimeric antibody; ANTI-CD20; MONOCLONAL-ANTIBODY; SYSTEMIC-LUPUS-ERYTHEMATOSUS; B-CELL DEPLETION; RITUXIMAB TREATMENT; EFFICACY; LYMPHOMA; PATIENT; SAFETY;
D O I
10.1007/s00467-014-2794-7
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Rituximab is actively used as a rescue therapy for nephrotic syndrome (NS). The development of antidrug antibodies, including antirituximab antibodies (ARA) and human antichimeric antibodies (HACA), is reported with rituximab treatment in various diseases. Here we report two pediatric patients with NS who developed ARA. Rituximab was given as a rescue therapy for two patients with steroid-dependent NS. Both patients had been treated orally with glucocorticosteroid, methylprednisolone, and calcineurin inhibitors but experienced frequent relapses. With rituximab treatment, the patients remained in remission for several months. After the B-cell count recovered, the patients received a second course of rituximab administration and experienced a hypersensitivity reaction during drug infusion. CD19 cell counts rose despite treatment with rituximab. ARA titers were monitored before and after rituximab treatment, and the development of ARA after the second course of rituximab administration was confirmed. We report the development of HACA in two patients with NS who did not achieve B-cell depletion after repeated administration of rituximab. This report suggests that additional studies are needed to determine the incidence of ARA in patients with NS, and its clinical significance.
引用
收藏
页码:1461 / 1464
页数:4
相关论文
共 15 条
[1]   Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus [J].
Albert, D. ;
Dunham, J. ;
Khan, S. ;
Stansberry, J. ;
Kolasinski, S. ;
Tsai, D. ;
Pullman-Mooar, S. ;
Barnack, F. ;
Striebich, C. ;
Looney, R. J. ;
Prak, E. T. Luning ;
Kimberly, R. ;
Zhang, Y. ;
Eisenberg, R. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (12) :1724-1731
[2]   Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy [J].
Cornec, Divi ;
Tempescul, Adrian ;
Querellou, Solene ;
Hutin, Pascal ;
Pers, Jacques-Olivier ;
Jamin, Christophe ;
Bendaoud, Boutahar ;
Berthou, Christian ;
Renaudineau, Yves ;
Youinou, Pierre .
ANNALS OF HEMATOLOGY, 2012, 91 (05) :715-721
[3]   Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:: Safety and efficacy of re-treatment [J].
Davis, TA ;
Grillo-López, AJ ;
White, CA ;
McLaughlin, P ;
Czuczman, MS ;
Link, BK ;
Maloney, DG ;
Weaver, RL ;
Rosenberg, J ;
Levy, R .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3135-3143
[4]   Rituximab treatment of idiopathic membranous nephropathy [J].
Fervenza, F. C. ;
Cosio, F. G. ;
Erickson, S. B. ;
Specks, U. ;
Herzenberg, A. M. ;
Dillon, J. J. ;
Leung, N. ;
Cohen, I. M. ;
Wochos, D. N. ;
Bergstralh, E. ;
Hladunewich, M. ;
Cattran, D. C. .
KIDNEY INTERNATIONAL, 2008, 73 (01) :117-125
[5]   Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura [J].
Goto, Shoko ;
Goto, Hiroaki ;
Tanoshima, Reo ;
Kato, Hiromi ;
Takahashi, Hiroyuki ;
Sekiguchi, Osamu ;
Kai, Sumio .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (03) :305-309
[6]   Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases [J].
Guigonis, Vincent ;
Dallocchio, Aymeric ;
Baudouin, Veronique ;
Dehennault, Maud ;
Camus, Caroline Hachon-Le ;
Afanetti, Mickael ;
Groothoff, Jaap ;
Llanas, Brigitte ;
Niaudet, Patrick ;
Nivet, Hubert ;
Raynaud, Natacha ;
Taque, Sophie ;
Ronco, Pierre ;
Bouissou, Francois .
PEDIATRIC NEPHROLOGY, 2008, 23 (08) :1269-1279
[7]   Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study [J].
Igarashi, T ;
Kobayashi, Y ;
Ogura, M ;
Kinoshita, T ;
Ohtsu, T ;
Sasaki, Y ;
Morishima, Y ;
Murate, T ;
Kasai, M ;
Uike, N ;
Taniwaki, M ;
Kano, Y ;
Ohnishi, K ;
Matsuno, Y ;
Nakamura, S ;
Mori, S ;
Ohashi, Y ;
Tobinai, K .
ANNALS OF ONCOLOGY, 2002, 13 (06) :928-943
[8]   Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome [J].
Kemper, Markus J. ;
Gellermann, Jutta ;
Habbig, Sandra ;
Krmar, Rafael T. ;
Dittrich, Katalin ;
Jungraithmayr, Therese ;
Pape, Lars ;
Patzer, Ludwig ;
Billing, Heiko ;
Weber, Lutz ;
Pohl, Martin ;
Rosenthal, Katrin ;
Rosahl, Anne ;
Mueller-Wiefel, Dirk E. ;
Doetsch, Joerg .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (05) :1910-1915
[9]   Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis [J].
Keystone, Edward ;
Fleischmann, Roy ;
Emery, Paul ;
Furst, Daniel E. ;
van Vollenhoven, Ronald ;
Bathon, Joan ;
Dougados, Maxime ;
Baldassare, Andrew ;
Ferraccioli, Gianfranco ;
Chubick, Andrew ;
Udell, James ;
Cravets, Matthew W. ;
Agarwal, Sunil ;
Cooper, Simon ;
Magrini, Fabio .
ARTHRITIS AND RHEUMATISM, 2007, 56 (12) :3896-3908
[10]   B cell depletion as a novel treatment for systemic lupus erythematosus - A phase I/II dose-escalation trial of rituximab [J].
Looney, RJ ;
Anolik, JH ;
Campbell, D ;
Felgar, RE ;
Young, F ;
Arend, LJ ;
Sloand, JA ;
Rosenblatt, J ;
Sanz, I .
ARTHRITIS AND RHEUMATISM, 2004, 50 (08) :2580-2589